ClinicalTrials.gg
CompletedNCT05552196Updated Apr 27, 2025

A Study of Ponesimod in Healthy Adult Participants

A Phase 1 interventional study of Ponesimod and Carbamazepine in Healthy, sponsored by Janssen Pharmaceutica N.V., Belgium. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of steady-state carbamazepine (CBZ; a strong pregnane X receptor [PXR] agonist) on the pharmacokinetics (PK) of ponesimod following a gradual up-titration regimen in healthy adult participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Pharmaceutica N.V., Belgium is the lead sponsor of 58 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between (BMI) 18-30 kilograms per meter square (kg/m\^2)
  • Willing and able to adhere to the prohibitions and restrictions.
  • Female participants with negative pregnancy test.
  • Women of (WOCBP) must use 2 methods of .
  • Healthy on the basis of physical examination (including neurological examination and skin examination), Columbia suicide severity rating scale questionnaire (C-SSRS) questionnaire, ophthalmological examination, medical history, vital signs, and 12-lead (ECG).
  • Positive varicella zoster virus (VZV).

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency ( below 60 milliliter per minute [mL/min]), thyroid disease, neurologic or psychiatric disease, confirmed or suspected macular edema, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
  • to the use of Carbamazepine (CBZ) as per local prescribing information
  • Any treatment within 6 weeks before first study drug administration.
  • Lymphopenia (less than 1,000 cells per microliter).
  • Received an drug or used an invasive investigational medical device within 30 days before the first study drug intake or received a biological product within 3 months or 5 half-lives (whichever is longer) before the first study drug intake, or is currently enrolled in an investigational study.
  • Lack of good/reasonable venous access.
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment A: Ponesimod

    Participants will receive up-titrated Ponesimod orally once daily from Day 1 to Day 15.

    Drug: Ponesimod

  • Experimental
    Treatment B: Ponesimod + Carbamazepine

    Participants will receive up-titrated Carbamazepine from Day 1 to Day 7 and from Day 23 to Day 26. Participants will also receive up-titrated Ponesimod and Carbamazepine from Day 8 to Day 22.

    Drug: Ponesimod · Drug: Carbamazepine

Interventions

  • Ponesimod tablet will be administered orally.

    Also known as: JNJ-67896153, ACT-128800, Ponvory

  • Carbamazepine tablet will be administered orally.

    Also known as: Tegretol

06

What researchers measure

Primary outcomes

  1. Treatment A: Cmax is the maximum Observed Plasma Concentration (Cmax) of Ponesimod

    Cmax is the maximum observed plasma concentration of Ponesimod.

    Time frame: Pre dose up to 120 hours post dose on Day 15

  2. Treatment A: Area Under The Plasma Concentration-time Curve of Ponesimod From Time 0 to 24 Hours Post Dose (AUC [0-24h])

    AUC (0-24h) is the plasma concentration-time curve of Ponesimod from time 0 to 24 hours post dose, calculated by linear-linear trapezoidal summation.

    Time frame: Pre dose up to 120 hours post dose on Day 15

  3. Treatment B: Cmax is the maximum Observed Plasma Concentration (Cmax) of Ponesimod

    Cmax is the maximum observed plasma concentration of Ponesimod.

    Time frame: Pre dose up to 120 hours post dose on Day 22

  4. Treatment B: Area Under The Plasma Concentration-time Curve of Ponesimod From Time 0 to 24 Hours Post Dose (AUC [0-24h])

    AUC (0-24h) is the plasma concentration-time curve of Ponesimod from time 0 to 24 hours post dose, calculated by linear-linear trapezoidal summation.

    Time frame: Pre dose up to 120 hours post dose on Day 22

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Up to Day 27

  2. Total Lymphocyte Count

    Total lymphocyte count will be reported.

    Time frame: Treatment A: Day 1 (Baseline) and Day 16; Treatment B: Day 1 (Baseline) and Day 23

  3. Percentage Change in Lymphocytes From Baseline

    Percentage change in lymphocytes from baseline will be reported.

    Time frame: Treatment A: Baseline and Day 16, Treatment B: Baseline and Day 23

07

Study locations

1 site
  • Clinical Pharmacology Unit
    Merksem, 2170, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Mar 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2022
First posted
Sep 23, 2022
StartActual
Oct 18, 2022
Primary completionActual
Mar 5, 2023
CompletionActual
Mar 29, 2023
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05552196
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Oct 18, 2022
Primary completion
Mar 5, 2023
Completion
Mar 29, 2023
Last update
Apr 27, 2025

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical Trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion